BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously...
Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 ...
BROOMFIELD, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging...
BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging...
Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028 ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo.,...
Expands availability of Nociscan in the greater Los Angeles area Reinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection...
BROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging...
Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025 Annual Nociscan scan volumes increased 69% year-over-year in 2025 Debt-free balance sheet with $12.0 million in cash as...
Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and...
Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study Special Pain issue features breakthrough innovations shaping the future of spine...